Add plain-language depression trial summary (#464)

depression_trial_summary.md

@@ -0,0 +1,110 @@
+# Plain-language summary: focused ultrasound in a small depression trial
+
+## What did the trial test?
+
+Researchers at the University of Arizona studied whether transcranial focused
+ultrasound (tFUS) could be delivered to a brain area involved in depression and
+whether participants' symptoms changed during the study. Transcranial means
+"through the skull." Focused ultrasound uses sound waves aimed at a specific
+location without surgery.
+
+The study enrolled 20 adults, ages 18 to 50, who were experiencing a major
+depressive episode and clinically significant repetitive negative thinking, such
+as persistent rumination or worry. Their depression was moderate to severe at
+enrollment. Half reported currently taking a psychiatric or other prescribed
+medication (most commonly an antidepressant), and participants were asked not to
+change their existing medication or psychotherapy regimens.
+
+A custom headset held a 128-element ultrasound array against the forehead. Each
+session delivered 10 minutes of low-intensity ultrasound to the left anterior
+medial prefrontal cortex. This region is a hub in the default mode network, a
+set of connected brain regions active during self-focused thought. Participants
+received five sessions during the first week. Those who did not meet the study's
+early-remission criteria could receive three sessions per week for two more
+weeks, for up to 11 sessions in total.
+
+## What did the researchers measure?
+
+The researchers assessed participants before treatment, after week 1, and, when
+applicable, after week 3. They used:
+
+- the Beck Depression Inventory-II (BDI-II), a 21-question self-report measure
+  of depression symptoms;
+- the Hamilton Depression Rating Scale (HDRS), a 17-item interview completed by
+  a clinician;
+- the Perseverative Thinking Questionnaire (PTQ), which measures repetitive
+  negative thinking; and
+- the World Health Organization Quality of Life questionnaire, covering
+  physical, psychological, social, and environmental well-being.
+
+The study also tracked suicidal thoughts, possible adverse events, sensations
+during sessions, and MRI findings that could indicate small brain bleeds.
+
+## What did the study find?
+
+At the start of the study, the average BDI-II score was 38.85. The paper's
+statistical model estimated that BDI-II scores decreased by 10.9 points for each
+step from baseline to week 1 to week 3. Figure 3 in the paper shows that the
+largest group-level decrease occurred during the first week, followed by a
+smaller decrease through week 3. The paper does not print exact group-average
+BDI-II scores for weeks 1 and 3, so they are not estimated here.
+
+By each participant's final assessment:
+
+- 12 of 20 participants (60%) had at least a 50% decrease from baseline on the
+  self-reported BDI-II;
+- 9 of 20 (45%) had at least a 50% decrease on the clinician-rated HDRS; and
+- 7 of 20 (35%) met the study's remission thresholds on both depression
+  measures: a BDI-II score below 13 and an HDRS score below 8.
+
+The average PTQ score also decreased over time. Physical and psychological
+quality-of-life scores and satisfaction with the participant's environment
+improved, while the change in social satisfaction was not statistically
+significant.
+
+Two participants stopped after week 1. The paper gives different explanations:
+the abstract says time constraints, while the Results and Discussion sections
+say lack of symptom improvement. It states that neither withdrawal was due to an
+adverse event. No serious adverse events were reported. Some participants
+described temporary discomfort, including tension or pain that they associated
+with headset tightness. Follow-up MRI readings showed no new microhemorrhages.
+No participant reported suicidal thoughts posing an imminent risk to themselves.
+One participant reported a temporary increase in suicidal thinking at the
+assessment after week 3, which the researchers attributed to a personal event (a
+relationship breakup) unrelated to the study procedure. These safety
+observations cover only this small group and short study period.
+
+## What do these results mean—and what do they not mean?
+
+The results show that delivering this form of focused ultrasound was feasible in
+this study and that depression symptoms decreased during the treatment period.
+They support further research, particularly a randomized trial that compares
+active ultrasound with a sham procedure.
+
+The study cannot show that ultrasound caused the improvement. It was an
+open-label, unblinded study: every participant knew they were receiving the
+procedure, and there was no control or sham group. Placebo effects, continued
+medication or psychotherapy, natural symptom changes, and other factors could
+have contributed. The study included only 20 people, followed outcomes for no
+more than three weeks, and enrolled a relatively young, predominantly female
+sample. It therefore cannot establish long-term benefit, uncommon risks, or how
+well the findings apply to other people with depression.
+
+The researchers targeted a hub of the default mode network, but this paper did
+not report whether the procedure changed that network's activity. That proposed
+mechanism remains a hypothesis. The University of Arizona investigator received
+an investigator-initiated grant from Openwater, and several coauthors were
+Openwater employees during parts of the study.
+
+These preliminary findings should not be used to replace established clinical
+care or to make treatment decisions.
+
+<!-- prettier-ignore -->
+> Openwater's platform is intended exclusively for research purposes and is not cleared or approved by the FDA for clinical use.
+
+## Where can I read more?
+
+- Schachtner, J. N., et al. (2025).
+  [Transcranial focused ultrasound targeting the default mode network for the treatment of depression](https://doi.org/10.3389/fpsyt.2025.1451828).
+  _Frontiers in Psychiatry, 16_, 1451828.
+- [ClinicalTrials.gov study record NCT06320028](https://clinicaltrials.gov/study/NCT06320028)